Summit Therapeutics' ivonescimab shows 27% lower mortality than Merck's Keytruda in lung cancer trial
Summit Therapeutics (SMMT) announced that its drug candidate, ivonescimab, significantly improved survival outcomes compared to Merck’s (MRK) Keytruda in a late-stage clinical trial for non-small cell lung cancer. The study was conducted by Summit's partner Akeso (AKESF) in China and showed a 27% reduction in the risk of death among patients treated with ivonescimab versus those receiving Keytruda. The results highlight potential competitive advantages for ivonescimab, particularly as immunotherapy remains a key treatment approach for lung cancer. The trial data could support further regulatory submissions and commercialization efforts if confirmed through additional studies or approvals.
Topics: cancer treatment clinical trials immunotherapy pharmaceuticals